Compare SY & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SY | CNTX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.8M | 283.9M |
| IPO Year | 2018 | 2021 |
| Metric | SY | CNTX |
|---|---|---|
| Price | $1.93 | $1.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $5.50 | ★ $6.60 |
| AVG Volume (30 Days) | ★ 860.8K | 626.5K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.64 | N/A |
| Revenue Next Year | $30.63 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $0.56 |
| 52 Week High | $6.28 | $3.62 |
| Indicator | SY | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.52 | 32.45 |
| Support Level | $1.86 | $0.95 |
| Resistance Level | $3.34 | $2.00 |
| Average True Range (ATR) | 0.21 | 0.22 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 5.88 | 0.36 |
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.